1
|
Bell KJ, Del Mar C, Wright G, Dickinson J
and Glasziou P: Prevalence of incidental prostate cancer: A
systematic review of autopsy studies. Int J Cancer. 137:1749–1757.
2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Lupu M, Caruntu A, Caruntu C, Papagheorghe
LML, Ilie MA, Voiculescu V, Boda D, Constantin C, Tanase C, Sifaki
M, et al: Neuroendocrine factors: The missing link in non melanoma
skin cancer (Review). Oncol Rep. 38:1327–1340. 2017. View Article : Google Scholar : PubMed/NCBI
|
3
|
Neagu M, Caruntu C, Constantin C, Boda D,
Zurac S, Spandidos DA and Tsatsakis AM: Chemically induced skin
carcinogenesis: Updates in experimental models (Review). Oncol Rep.
35:2516–2528. 2016. View Article : Google Scholar : PubMed/NCBI
|
4
|
Boda D: Cellomics as integrative omics for
cancer. Curr Proteomics. 10:237–245. 2013. View Article : Google Scholar
|
5
|
Neagu M, Constantin C, Tanase C and Boda
D: Patented biomarker panels in early detection of cancer. Recent
Pat Biomark. 1:10–24. 2011. View Article : Google Scholar
|
6
|
Boda D, Docea AO, Calina D, Ilie MA,
Caruntu C, Zurac S, Neagu M, Constantin C, Branisteanu DE,
Voiculescu V, et al: Human papilloma virus: Apprehending the link
with carcinogenesis and unveiling new research avenues (Review).
Int J Oncol. 52:637–655. 2018.PubMed/NCBI
|
7
|
Solomon I, Voiculescu VM, Caruntu C, Lupu
M, Popa A, Ilie MA, Albulescu R, Caruntu A, Tanase C, Constantin C,
et al: Neuroendocrine factors and head and neck squamous cell
carcinoma: An affair to remember. Dis Markers. 2018:97878312018.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Lupu M, Caruntu A, Caruntu C, Boda D,
Moraru L, Voiculescu V and Bastian A: Non-invasive imaging of
actinic cheilitis and squamous cell carcinoma of the lip. Mol Clin
Oncol. 8:640–646. 2018.PubMed/NCBI
|
9
|
Voiculescu VM, Caruntu C, Solomon I, Lupu
M, Ilie MA, Boda D, Constantin C and Neagu M: Squamous cell
carcinoma: Biomarkers and potential therapeutic targetsHuman Skin
Cancers-Pathways, Mechanisms, Targets and Treatments. Blumenberg M:
IntechOpen; London: pp. 135–159. 2018
|
10
|
Rosenbaum E, Partin A and Eisenberger MA:
Biochemical relapse after primary treatment for prostate cancer:
Studies on natural history and therapeutic considerations. J Natl
Compr Canc Netw. 2:249–256. 2004. View Article : Google Scholar : PubMed/NCBI
|
11
|
Beauval J-B, Roumiguié M, Filleron T,
Benoit T, de la Taille A, Malavaud B, Salomon L, Soulié M and
Ploussard G: Biochemical recurrence-free survival and pathological
outcomes after radical prostatectomy for high-risk prostate cancer.
BMC Urol. 16:262016. View Article : Google Scholar : PubMed/NCBI
|
12
|
Ozden C, Aktas BK, Bulut S, Erbay G, Tagci
S, Gokkaya CS, Baykam MM and Memis A: Effect of age on biochemical
recurrence after radical prostatectomy. Kaohsiung J Med Sci.
33:91–95. 2017. View Article : Google Scholar : PubMed/NCBI
|
13
|
Pound CR, Partin AW, Eisenberger MA, Chan
DW, Pearson JD and Walsh PC: Natural history of progression after
PSA elevation following radical prostatectomy. JAMA. 281:1591–1597.
1999. View Article : Google Scholar : PubMed/NCBI
|
14
|
Boorjian SA, Thompson RH, Tollefson MK,
Rangel LJ, Bergstralh EJ, Blute ML and Karnes RJ: Long-term risk of
clinical progression after biochemical recurrence following radical
prostatectomy: The impact of time from surgery to recurrence. Eur
Urol. 59:893–899. 2011. View Article : Google Scholar : PubMed/NCBI
|
15
|
Gomez P, Manoharan M, Kim SS and Soloway
MS: Radionuclide bone scintigraphy in patients with biochemical
recurrence after radical prostatectomy: When is it indicated? BJU
Int. 94:299–302. 2004. View Article : Google Scholar : PubMed/NCBI
|
16
|
Beresford MJ, Gillatt D, Benson RJ and
Ajithkumar T: A systematic review of the role of imaging before
salvage radiotherapy for post-prostatectomy biochemical recurrence.
Clin Oncol (R Coll Radiol). 22:46–55. 2010. View Article : Google Scholar : PubMed/NCBI
|
17
|
Karakiewicz PI, Eastham JA, Graefen M,
Cagiannos I, Stricker PD, Klein E, Cangiano T, Schröder FH,
Scardino PT and Kattan MW: Prognostic impact of positive surgical
margins in surgically treated prostate cancer: Multi-institutional
assessment of 5831 patients. Urology. 66:1245–1250. 2005.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Daly T, Hickey BE, Lehman M, Francis DP
and See AM: Adjuvant radiotherapy following radical prostatectomy
for prostate cancer. Cochrane Database Syst Rev.
12:CD0072342011.
|
19
|
Trock BJ, Han M, Freedland SJ, Humphreys
EB, DeWeese TL, Partin AW and Walsh PC: Prostate cancer-specific
survival following salvage radiotherapy vs observation in men with
biochemical recurrence after radical prostatectomy. JAMA.
299:2760–2769. 2008. View Article : Google Scholar : PubMed/NCBI
|
20
|
King CR: The dose-response of salvage
radiotherapy following radical prostatectomy: A systematic review
and meta-analysis. Radiother Oncol. 121:199–203. 2016. View Article : Google Scholar : PubMed/NCBI
|
21
|
Ghadjar P, Hayoz S, Bernhard J, Zwahlen
DR, Hölscher T, Gut P, Guckenberger M, Hildebrandt G, Müller AC,
Plasswilm L, et al: Acute toxicity and quality of life after
dose-intensified salvage radiation therapy for biochemically
recurrent prostate cancer after prostatectomy: First results of the
randomized trial SAKK 09/10. J Clin Oncol. 33:4158–4166. 2015.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Goenka A, Magsanoc JM, Pei X, Schechter M,
Kollmeier M, Cox B, Scardino PT, Eastham JA and Zelefsky MJ:
Improved toxicity profile following high-dose postprostatectomy
salvage radiation therapy with intensity-modulated radiation
therapy. Eur Urol. 60:1142–1148. 2011. View Article : Google Scholar : PubMed/NCBI
|
23
|
European Association of Urology, .
Guidelines on Prostate Cancer 2018. Chapter 625. https://uroweb.org/guideline/prostate-cancer/#6February
13–2019
|
24
|
Tendulkar RD, Agrawal S, Gao T, Efstathiou
JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY,
Liauw SL, et al: Contemporary update of a multi-institutional
predictive nomogram for salvage radiotherapy after radical
prostatectomy. J Clin Oncol. 34:3648–3654. 2016. View Article : Google Scholar : PubMed/NCBI
|
25
|
Hwang WL, Tendulkar RD, Niemierko A,
Agrawal S, Stephans KL, Spratt DE, Hearn JW, Koontz BF, Lee WR,
Michalski JM, et al: Comparison between adjuvant and early-salvage
postprostatectomy radiotherapy for prostate cancer with adverse
pathological features. JAMA Oncol. 4:e1752302018. View Article : Google Scholar : PubMed/NCBI
|
26
|
Shipley WU, Seiferheld W, Lukka HR, Major
PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman
AL, et al NRG Oncology RTOG, : Radiation with or without
antiandrogen therapy in recurrent prostate cancer. N Engl J Med.
376:417–428. 2017. View Article : Google Scholar : PubMed/NCBI
|
27
|
Carrie C, Hasbini A, de Laroche G, Richaud
P, Guerif S, Latorzeff I, Supiot S, Bosset M, Lagrange JL,
Beckendorf V, et al: Salvage radiotherapy with or without
short-term hormone therapy for rising prostate-specific antigen
concentration after radical prostatectomy (GETUG-AFU 16): A
randomised, multicentre, open-label phase 3 trial. Lancet Oncol.
17:747–756. 2016. View Article : Google Scholar : PubMed/NCBI
|
28
|
Mottet N, Bellmunt J, Bolla M, Briers E,
Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau
S, et al: EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1:
Screening, diagnosis, and local treatment with curative intent. Eur
Urol. 71:618–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
29
|
Garcia-Albeniz X, Chan JM, Paciorek A,
Logan RW, Kenfield SA, Cooperberg MR, Carroll PR and Hernán MA:
Immediate versus deferred initiation of androgen deprivation
therapy in prostate cancer patients with PSA-only relapse. An
observational follow-up study. Eur J Cancer. 51:817–824. 2015.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Loeb S, Feng Z, Ross A, Trock BJ,
Humphreys EB and Walsh PC: Can we stop prostate specific antigen
testing 10 years after radical prostatectomy? J Urol. 186:500–505.
2011. View Article : Google Scholar : PubMed/NCBI
|
31
|
Solovastru LG, Vata D, Statescu L,
Constantin MM and Andrese E: Skin cancer between myth and reality,
yet ethically constrained. Rev Rom Bioet. 12:47–52. 2014.
|
32
|
Sinescu I, Geavlete P, Multescu R, Gangu
C, Miclea F, Coman I, Ioiart I, Ambert V, Constantin T, Petrut B
and Feciche B: Long-term efficacy of Serenoa repens treatment in
patients with mild and moderate symptomatic benign prostatic
hyperplasia. Urol Int. 86:284–289. 2011. View Article : Google Scholar : PubMed/NCBI
|
33
|
Constantin TV, Madan VL, Constantin MM,
Morariu SH and Braticevici B: The role of prostate-specific antigen
in prostate cancer screening. Rev Rom Med Lab. 22:275–281. 2014.(In
Romanian).
|
34
|
Spinu D, Bratu O, Marcu D, Mischianu D,
Huica R, Surcel M, Munteanu A, Socea B, Bodean O and Ursaciuc C:
The use of ELISA and PCR in identifying correlations between viral
infections and benign prostatic hypertrophy. Rev Chim Buchar.
69:645–649. 2018.
|
35
|
Popescu R, Bratu O, Spinu D, Marcu D,
Farcas C, Dinu M and Mischianu D: Neuroendocrine differentiation in
prostate cancer - a review. Rom J Mil Med. 118:16–19. 2015.
|
36
|
Marcu D, Spinu D, Mischianu D, Socea B,
Oprea I and Bratu O: Oncological follow-up after radical
prostatectomy. Rom J Mil Med. 120:39–42. 2017.
|
37
|
Socea LI, Visan DC, Barbuceanu SF, Apostol
TV, Bratu OG and Socea B: The antioxidant activity of some
acylhydrazones with dibenzo[a,d][7]annulene moiety. Rev Chim
Buchar. 69:795–797. 2018.
|
38
|
Radulescu A, Madan V, Aungurenci A, Bratu
O, Farcas C, Dinu M and Mischianu D: Antibiotic resistant urinary
tract infections in a urology ward. Rom J Mil Med. 118:20–22.
2015.
|
39
|
Spinu D, Bratu O, Popescu R, Marcu D,
Radulescu A and Mischianu D: Clostridium difficile - an emerging
plague. Rom J Mil Med. 118:12–15. 2015.
|
40
|
Ahove DA, Hoffman KE, Hu JC, Choueiri TK,
D'Amico AV and Nguyen PL: Which patients with undetectable PSA
levels 5 years after radical prostatectomy are still at risk of
recurrence? - Implications for a risk-adapted follow-up strategy.
Urology. 76:1201–1205. 2010. View Article : Google Scholar : PubMed/NCBI
|
41
|
Vasto S, Carruba G, Lio D, Colonna-Romano
G, Di Bona D, Candore G and Caruso C: Inflammation, ageing and
cancer. Mech Ageing Dev. 130:40–45. 2009. View Article : Google Scholar : PubMed/NCBI
|